Berkeley Haas Case Series
The Berkeley Haas Case Series is a collection of business case studies created by UC Berkeley faculty
by Larry Lasky
The Intellikine case study provides an example of a biotech company where its management team, founders, and investors sold the company at a relatively early stage of the company's development. In early 2012, Troy Wilson, the CEO of Intellikine sold the company to Millennium - The Takeda Oncology Company, Takeda's business unit responsible for global oncology, strategy, and development. The deal was for as much as $310 million (Millennium would pay $190 million upfront, with an additional $120 million dependent on clinical development milestones). By 2011, the Intellikine team had advanced three programs into human clinical testing. The key question for students is whether Wilson and his team sold the company too early or not. Various perspectives and the company strategy and execution are provided in the case study to allow students to have a fruitful discussion on each side of the argument.
Pub Date: Jan 31, 2013
Discipline: Entrepreneurship
Subjects: Health care, Startup, Mergers & acquisitions, Entrepreneurship, Innovation, Leadership, Corporate strategy, Start-ups
Product #: B5763-PDF-ENG
Industry: Biotechnology,Pharmaceuticals
Geography: United States, California
Length: 11 page(s)
